Tags · Evidence

preprint

Not yet peer reviewed. Labelled every time.

56 topics 23 solved Group: Evidence

56 topics · page 2 of 2

Topic	Participants	Replies	Views	Activity
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Glucagon receptor…		4	3.7k	10mo
Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? Evidence › Preprints preprint needs a source effect size Solved Under review The question in the title: Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? I will give what I have already checked below so nobody repeats it. A question about…	+103	115	24k	10mo
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…	+114	120	1.4k	10mo
BPC-157: what the rodent literature actually shows, and what it does not Compounds › Repair & healing peptides observational data preprint BPC-157 needs a source BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I would like to know what people here actually do about BPC-157,…	+44	48	3k	10mo
Analytical identity of BPC-157: a 15-mer with a simple mass Compounds › Repair & healing peptides BPC-157 observational data needs a source preprint Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did. Something about analytical identity of BPC-157 does not reconcile…	+3	7	5.2k	10mo
The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide preprint effect size TRIUMPH programme Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Retatrutide phase 2 obesity paper, from the point of view of someone…		2	65k	10mo
When a preprint is the best available evidence and we say so Evidence › Preprints risk of bias effect size preprint Solved When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. A preprint question rather than a question about the…	+148	160	31k	11mo
[2026 update] What we do not know about retatrutide, listed explicitly Compounds › Retatrutide TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question…	+79	83	952	11mo
TB-500 and thymosin beta-4: the fragment versus the protein Compounds › Repair & healing peptides observational data TB-500 BPC-157 preprint TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did. TB-500 and thymosin beta-4: what I expected, what I found, and…	+107	118	22k	11mo
The "under review" status pill and when a moderator applies it — a second dataset Evidence › Preprints needs a source risk of bias preprint effect size The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A question about how this site should cite…	+50	54	1.4k	11mo
Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide retatrutide effect size preprint Solved The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Asking about triple agonism on behalf of the question I keep…	+71	80	38k	11mo
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Compounds › Repair & healing peptides TB-500 preprint observational data needs a source Solved On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…	+77	84	54k	11mo
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide randomised trial preprint effect size retatrutide Solved Closed On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. Asking about retatrutide phase 2 in type on behalf of the question I keep seeing…	+12	16	50k	12mo
Why plausible mechanism is not evidence of effect — one year on Compounds › Repair & healing peptides needs a source preprint BPC-157 Solved Closed The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. What changes if the standard account of plausible…	+3	7	3.6k	13mo
Why plausible mechanism is not evidence of effect Compounds › Repair & healing peptides TB-500 preprint observational data Solved Closed Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect What changes if the standard account of plausible mechanism is wrong? I ask because I have been…	+14	18	57k	13mo
When a preprint is the best available evidence and we say so — a second dataset Evidence › Preprints preprint risk of bias needs a source Solved When a preprint is the best available evidence and we say so — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. A preprint question rather than a…	+20	24	36k	14mo
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. A follow-up question about Oral versus injected administration claims…	+23	27	7.7k	15mo
Retatrutide dose escalation in the published trials Compounds › Retatrutide preprint retatrutide effect size Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…	+149	159	30k	15mo
What we do not know about retatrutide, listed explicitly Compounds › Retatrutide retatrutide effect size preprint TRIUMPH programme The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Setting out what I think I know about this compound and…	+106	113	4.8k	17mo
What would change my mind about repair peptides: a specific answer — one year on Compounds › Repair & healing peptides needs a source observational data TB-500 preprint Closed What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Documentation question rather than a…	+9	13	42k	19mo
Reading a preclinical wound-healing model and its relevance to a human tendon Compounds › Repair & healing peptides TB-500 preprint observational data Wiki Closed On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. Posting a small dataset on reading a preclinical…	+149	160	3.3k	20mo
Tracking a preprint to publication: a worked example — the long version Evidence › Preprints risk of bias preprint effect size Posting this under the heading it deserves: Tracking a preprint to publication: a worked example — the long version Everything below is what sits behind that. A preprint question rather than a question about…	+38	47	560	22mo
Why a preprint's supplementary material is often the best part Evidence › Preprints needs a source risk of bias preprint effect size Why a preprint's supplementary material is often the best part I have a specific reason for asking rather than idle curiosity, and the context is below. A question about how this site should cite something…	+38	42	863	22mo
Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide TRIUMPH programme effect size preprint randomised trial Solved Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…	+51	56	700	22mo
How this community labels and discusses unrefereed work Evidence › Preprints risk of bias effect size preprint needs a source How this community labels and discusses unrefereed work — that is the question, and I have not found it answered plainly anywhere I have looked. Reading an unrefereed manuscript properly, and asking whether I…	+112	119	1.3k	2y
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…	+115	125	30k	2y